Clinical trial
Clinical Study of PIC1 Injection for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT07456371 is registered in ClinicalTrials.gov with Chongqing Precision Biotech Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Clinical Study of PIC1 Injection for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Lead sponsor
- Chongqing Precision Biotech Co., Ltd
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- March 31, 2026
- Completion date
- February 28, 2029
- Enrollment
- 18 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
non-hodgkin lymphoma